, Volume 206, Issue 1, pp 155–165 | Cite as

Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats

  • Sara Jane Ward
  • Timothy W. Lefever
  • Scott M. Rawls
  • Garth T. Whiteside
  • Ellen A. Walker
Original Investigation



The cannabinoid CB1 selective antagonist SR141716A (Rimonabant) has been shown to decrease body weight in laboratory animals and humans. Furthermore, SR141716A can elicit scratching behavior in rodents, a behavior that has been hypothesized to contribute to SR141716A-induced decrease in food intake. Although childhood obesity is a rising health issue, it is unknown whether SR141716A is equipotent at modulating food intake and other CB1-mediated behaviors in younger subjects.


To determine whether CB1 receptor blockade is equipotent at modulating food and water intake, body weight, and scratching behavior, the effect of a range of SR141716A doses on these behaviors in food-restricted postnatal day (P) 18, 28, and 60 male rats was investigated. Brain concentrations of SR141716A were determined in each age group.


SR141716A dose- and age-dependently suppressed food and water intake and body weight gain and elicited head scratching, with the most potent effects observed in P18 and P28 rats. Brain concentrations of SR141716A were significantly elevated in P18 rats relative to P28 and P60 rats. SR141716A-elicited head scratching was attenuated by the 5-HT2A/2C antagonist ketanserin.


SR141716A is more potent at modulating food intake and head scratching in very young animals; these differences can be attributed to an increase in brain penetration of SR141716A for P18 but not for P28 and P60 rats. In addition, SR141716-elicited head scratching is modulated by 5HT receptor antagonism and is not a contributing factor to SR141716A's anorectic effects.


Cannabinoid CB1 Age Development Food intake Body weight Scratching Itch SR141716A Ketanserin 


  1. Arnone M, Maruani J, Chaperon F, Thiébot MH, Poncelet M, Soubrié P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132(1):104–106PubMedCrossRefGoogle Scholar
  2. Belue RC, Howlett AC, Westlake TM, Hutchings DE (1995) The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol Teratol 17(1):25–30PubMedCrossRefGoogle Scholar
  3. Bolles RC (1961) The interaction of hunger and thirst in the rat. J Comp Physiol Psychol 54:580–584PubMedCrossRefGoogle Scholar
  4. Cizek LJ, Nocenti MR (1965) Relationship between water and food ingestion in the rat. Am J Physiol 208:615–620PubMedGoogle Scholar
  5. Cook SA, Lowe JA, Martin BR (1998) CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 285(3):1150–1156PubMedGoogle Scholar
  6. Darmani NA, Pandya DK (2000) Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J Neural Transm 107(8–9):931–945PubMedCrossRefGoogle Scholar
  7. Després JP, Golay A, Sjöström L (2005) Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353(20):2121–2134PubMedCrossRefGoogle Scholar
  8. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410(6830):822–825PubMedCrossRefGoogle Scholar
  9. Dvorak M, Watkinson A, McGlone F, Rukwied R (2003) Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 52(6):238–245PubMedGoogle Scholar
  10. European Medicines Agency Acomplia European Public Assessment Report (2009)
  11. Gardner A, Mallet PE (2006) Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor ‘silent antagonist’. Eur J Pharmacol 530(1–2):103–106PubMedCrossRefGoogle Scholar
  12. Gueudet C, Santucci V, Rinaldi-Carmona M, Soubrié P, Le Fur G (1995) The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat. Neuroreport 6(10):1421–1425PubMedCrossRefGoogle Scholar
  13. Janoyan JJ, Crim JL, Darmani NA (2002) Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids. Pharmacol Biochem Behav 71(1–2):155–162PubMedCrossRefGoogle Scholar
  14. Järbe TU, Andrzejewski ME, DiPatrizio NV (2002) Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73(4):911–919PubMedCrossRefGoogle Scholar
  15. Johansson JO, Jarbe TU, Henriksson BG (1975) Acute and subchronic influences of tetrahydrocannabinols on water and food intake, body weight, and temperature in rats. TIT J Life Sci 5(1–2):17–27PubMedGoogle Scholar
  16. Jourdan D, Piec I, Gaulier JM, Lacassie E, Alliot J (2003) Effect of fenfluramine on caloric intake and macronutrient selection in Lou/c rats during aging. Neurobiol Aging 24(1):67–76PubMedCrossRefGoogle Scholar
  17. McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ, Betz AJ, Ishiwari K, Makriyannis A, Salamone JD (2003) The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 14(8):583–588PubMedCrossRefGoogle Scholar
  18. McLaughlin PJ, Winston KM, Limebeer CL, Parker LA, Makriyannis A, Salamone JD (2005) The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology 180(2):286–293PubMedCrossRefGoogle Scholar
  19. Miller CC, Murray TF, Freeman KG, Edwards GL (2004) Cannabinoid agonist, CP 55, 940, facilitates intake of palatable foods when injected into the hindbrain. Physiol Behav 80(5):611–616PubMedCrossRefGoogle Scholar
  20. Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, Jeffers L, Schiff E (2002) Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 97(8):2117–2119PubMedCrossRefGoogle Scholar
  21. Oluyomi AO, Datla KP, Curzon G (1994) Effects of d-fenfluramine on feeding and hypothalamic 5-hydroxytryptamine and dopamine in male and female rats. Eur J Pharmacol 255(1–3):175–183PubMedCrossRefGoogle Scholar
  22. Pavon FJ, Bilbao A, Hernández-Folgado L, Cippitelli A, Jagerovic N, Abellán G, Rodríguez-Franco MA, Serrano A, Macias M, Gómez R, Navarro M, Goya P, Rodríguez de Fonseca F (2006) Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-3-hexyl-1H–1, 2, 4-triazole–LH 21. Neuropharmacology 51(2):358–366PubMedCrossRefGoogle Scholar
  23. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295(7):761–775PubMedCrossRefGoogle Scholar
  24. Rodríguez de Fonseca F, Ramos JA, Bonnin A, Fernández-Ruiz JJ (1993) Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4(2):135–138PubMedCrossRefGoogle Scholar
  25. Rowland ME, Mukherjee M, Robertson K (2001) Effects of the cannabinoid receptor antagonist SR141716 alone and in combination with dexfenfluramine or naloxone on food intake in rats. Psychopharmacology 159(1):111–116PubMedCrossRefGoogle Scholar
  26. Rubino T, Patrini G, Massi P, Fuzio D, Viganò D, Giagnoni G, Parolaro D (1998) Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 285(2):813–819PubMedGoogle Scholar
  27. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368(9548):1660–1672PubMedCrossRefGoogle Scholar
  28. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R (2005) Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38(3):177–188PubMedCrossRefGoogle Scholar
  29. Szepietowski JC, Szepietowski T, Reich A (2005) Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 13(2):97–103PubMedGoogle Scholar
  30. Tallett AJ, Blundell JE, Rodgers RJ (2007) Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology 195(1):27–39PubMedCrossRefGoogle Scholar
  31. Traynor K (2007) Panel advises against rimonabant approval. Am J Health-Syst Pharm 64(14):1460–1461PubMedGoogle Scholar
  32. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365(9468):1389–1397PubMedCrossRefGoogle Scholar
  33. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA (2003) Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 167(1):103–111PubMedGoogle Scholar
  34. Wang Y, Lobstein T (2006) Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 1(1):11–25PubMedCrossRefGoogle Scholar
  35. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A 100(3):1393–1398PubMedCrossRefGoogle Scholar
  36. Ward SJ, Dykstra LA (2005) The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 16:381–388PubMedCrossRefGoogle Scholar
  37. Williams CM, Kirkham TC (1999) Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 143(3):315–317PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Sara Jane Ward
    • 1
  • Timothy W. Lefever
    • 1
  • Scott M. Rawls
    • 1
  • Garth T. Whiteside
    • 2
  • Ellen A. Walker
    • 1
  1. 1.Department of Pharmaceutical SciencesTemple University School of PharmacyPhiladelphiaUSA
  2. 2.Neuroscience Discovery ResearchWyeth ResearchPrincetonUSA

Personalised recommendations